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Abstract
Background Synthetic cannabinoids (SCs) are a class of new psychoactive substances that have been rapidly evolving around the
world throughout recent years. Many different synthetic cannabinoid analogues are on the consumer market and sold under
misleading names, like Bspice^ or Bincense.^A limited number of studies have reported serious health effects associated with SC
use. In this study, we compared clinical and subclinical psychopathological symptoms associated with SC use and natural
cannabis (NC) use.
Methods A convenience sample of 367 NC and SC users was recruited online, including four validated psychometric question-
naires: The Drug Use Disorders Identification Test (DUDIT), Insomnia Severity Index (ISI), Altman Mania Scale (Altman), and
Brief Symptom Inventory (BSI). The two groups were compared with analysis of variance (ANOVA) and covariance
(ANCOVA), chi2 tests, and logistic regression when appropriate.
Results The SC user group did not differ in age from the NC user group (27.7 years), but contained less females (21% and 30%,
respectively). SC users scored higher than NC users on all used psychometric measures, indicating a higher likelihood of drug
abuse, sleep problems, (hypo)manic symptoms, and the nine dimensions comprising the BSI, somatization, obsessive-
compulsive behavior, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, and psychoticism.
Odds ratios (95% CI) for the SC user group vs NC user group were, respectively, drug dependence 3.56 (1.77–7.16), (severe)
insomnia 5.01 (2.10–11.92), (hypo-)mania 5.18 (2.04–13.14), and BSI psychopathology 5.21 (2.96–9.17).
Discussion This study shows that SC use is associated with increased mental health symptomatology compared to NC use.
Keywords Cannabis . Synthetic cannabis . Spice .Mental health . Psychology . Psychiatry . Questionnaire . BSI . ISI . Altman .
DUDIT
Introduction
There has been a dramatic increase in the diversity of new
psychoactive substances (NPS) that are being sold as
recreational drugs on the consumer market, mostly through
the internet (European Monitoring Centre for Drugs and
Drug Addiction 2015, 2017). The number of different NPS
that has been reported to the early warning system of the
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European Union is already up to 600 since 2005 and is still
increasing. Whereas the diffusion of NPS on the consumer
market initially started out with stimulants, such as synthetic
cathinones (Bossong et al. 2005; Brunt et al. 2011), these were
followed by a wide array of other chemicals belonging to a
range of drug classes. These include hallucinogens such as n-
benzyl-oxy-methyl derivatives (NBOMes) and the 2C-class
drugs (Burns et al. 2014; Caudevilla-Gálligo et al. 2012;
Hondebrink et al. 2015), entactogens such as benzofurans
(Hondebrink et al. 2015; Soh and Elliott 2014) and synthetic
opioids and the cannabis analogues, synthetic cannabinoids
(SCs) (Martinotti et al. 2017).
SCs refer to herbal or powder preparations containing syn-
thetic cannabinoid receptor agonists. SCs were originally devel-
oped in order to investigate the selective therapeutic effects of
Δ9-tetrahydrocannabinol (THC) and the role of the
endocannabinoid system by selectively targeting cannabinoid
receptors (Pertwee 2006; Huffman et al. 1996). In fact, some
potential for therapeutic purposes was found for certain synthet-
ic cannabinoid agonists and antagonists (De Luca and Fattore
2018;Muller et al. 2019). The SCs currently used recreationally
are potent cannabinoid receptor agonists often synthesized in
clandestine laboratories in China with a much higher receptor
affinity andmore intense psychoactive effects than THC, which
is a partial agonist of these receptors (Castaneto et al. 2014;
ElSohly et al. 2014; European Monitoring Centre for Drugs
and Drug Addiction 2017; Hoffman et al. 2017; Schifano
et al. 2015; van Amsterdam et al. 2015).
SCs form the largest category of NPS: they represent 32%
of all NPS and a total of over 240 different SCs have been
reported to the United Nations Office on Drugs and Crime by
65 member states (United Nations Office on Drugs and Crime
2017). In addition, the quantity of SCs seized between 2010
and 2015 showed a sharp increase. SCs are usually sold in
colorful packaging marked with labels to suggest that it is not
for human consumption, such as Bincense^ or Bspice^ in order
to mislead and circumvent drug laws. Different countries have
different laws concerning SCs, sometimes via compound-
specific bans or via generic cannabinoid analogue legislation
by a blanket ban. SCs are still easily obtained however, espe-
cially via the internet (European Monitoring Centre for Drugs
and Drug Addiction 2015, 2017). SCs are mainly used out of
curiosity, to avoid detection in routine drug tests, and because
of availability and non-illegality (Vandrey et al. 2012;
Winstock and Barratt 2013).
The relatively high potency compared to natural cannabis
and increasing prevalence of use of SCs together with an
unfamiliarity with their effects have led to an increase in the
number of cases with acute SC intoxication around the world.
In Russia, Poland, and the USA, SCs have been associated
with poisoning and deaths (Adamowicz 2016; Law et al.
2015; Shevyrin et al. 2015). Systematic data on prevalence
is scarce, partly because SCs do not show up in most standard
toxicological screens in saliva or urine. In the USA, the num-
ber of emergency department visits related to SCs increased
from 11,406 to 28,531 between 2010 and 2011 (Bush and
Woodwell 2013). In Europe, SCs were reported in 0.3% of
all drug toxicity cases in 16 emergency rooms (Dines et al.
2015). Most patients present with relatively mild physical
(nausea, shortness of breath, hypertension) and mental (rest-
lessness, agitation, and anxiety) symptoms and recover within
24 h with supportive care. In some cases, however, patients
are hospitalized for serious physical (myocardial infarction,
stroke, seizures, kidney injury) and mental (psychosis, para-
noia) complications associated with SC use (Castaneto et al.
2014; Musshoff et al. 2014; Tait et al. 2016). While causality
is difficult to establish, and many SC users also use other
drugs (Winstock and Barratt 2013), case studies suggested
that SC use is able to trigger long-term psychotic symptoms
in otherwise healthy individuals (Fattore 2016). Furthermore,
among psychiatric patients, SC users presented with more
severe psychotic symptoms and agitation compared to natural
cannabis (NC) users (Bassir Nia et al. 2016; Shalit et al. 2016).
While this data from emergency rooms and clinics highlights
the risks associated with SCs, little is known about the majority
of recreational users, not admitted in any health care system. A
couple of studies have appeared recently, indicating a higher
proneness to abuse or risk-taking behavior in adolescent users
of SC compared to users of natural cannabis (Clayton et al.
2017; Blevins et al. 2016). From online discussions we know
that recreational users report acute symptoms very similar to
those observed in emergency rooms, both physically (tachycar-
dia, respiratory issues, nausea) and mentally (fear, memory im-
pairment), in addition to sub-acute (hangovers, lethargy) and
longer-term issues (dependence, memory impairment, mood
swings) (Soussan and Kjellgren 2014). This study aims to
quantify a wide range of psychopathological symptoms in a
group of recreational SC users in a non-clinical setting and
compare them to natural cannabis (NC) users.
Methods
Sample
This convenience sample included SC and NC users, re-
cruited in three European countries (United Kingdom,
Sweden, and the Netherlands). The subjects have been
contacted through social media (Facebook, Twitter) and
by drug-related forums that are the most used sales/
diffusion channels, as reported by a review (Miliano et al.
2018). The online drug-related forums included www.
flashback.org and www.bluelight.org, from January to
June 2017. As prevalence of SC use is rather uncertain, we
directed most effort into recruiting users of SC through the
various nightlife and drug-related forums and social media.
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Inclusion criteria for the participants were that they had
used either natural cannabis and/or synthetic cannabinoids in
the past 12 months and were 18 years of age or older.
Participants were obligated to give online informed consent
before filling out the survey and time to complete the survey
took approximately 25 min. The study was approved by the
research ethical committee of Maastricht University.
Survey and psychometric measures
First of all, the survey started with some demographic items,
like age, gender, education, work status, and housing status.
The next part dealt with substance use history, in which last
year use and past use (last 2 weeks) was asked for several
substances, including alcohol and tobacco.
To get a broad overview of any potential psychological prob-
lems, four standardized psychometric instruments were used,
based on symptoms that were frequentlymentioned in relationship
to (synthetic) cannabinoids in scientific literature (e.g., depression,
psychosis, anxiety, sleep disorders, abuse, and dependence):
To assess the level of substance abuse problems in both
groups, we used the 11-item Drug Use Disorders
Identification Test (DUDIT) (Berman et al. 2005; Hildebrand
2015). The DUDIT consists of nine questions on a 5-point
scale, and two questions on a 3-point scale, all of which con-
tribute to a total score which can fall in three categories: no
problems, substance abuse (6+), or substance dependence
(20+). To assess any problems surrounding sleep disturbances
and insomnia, the Insomnia Severity Index (ISI) was used
(Morin et al. 2011). This is a 7-item questionnaire where the
participants rate sleep-related problems on a 5-point scale
which all contribute to a total score which can be categorized
as no problems, subthreshold insomnia (8+), clinical insomnia
(15+), and severe clinical insomnia (22+). The Altman Self-
Rating Mania Scale (Altman) contains 5 questions which are
answered on a 5-point scale and is used to assess the presence
and severity of (hypo)manic symptoms (Altman et al. 2001;
Altman et al. 1997). The total score on these 5 questions can
be categorized as no symptoms, or a high probability of a
(hypo)manic condition (6+). To gain insight into any other
mental problems, the Brief Symptom Inventory (BSI) was used
(Derogatis 1993). It contains 53 questions which are answered
on a 5-point Likert scale. Each question contributes to a global
severity index as well as one of nine psychopathological dimen-
sions: somatization, obsessive-compulsive, interpersonal sensi-
tivity, depression, anxiety, hostility, phobic anxiety, paranoid
ideation, and psychoticism.
Statistics
First, we compared the SC and NC user groups to each other on
age using analysis of variance (ANOVA) and gender using a
chi2 test. For our main analyses, we compared the SC users to
the NC users. We compared the SC and NC user groups on age
using ANOVA, and gender, frequency of use, and use of other
drugs using chi2 tests. We then compared both groups on the
primary outcome measures (DUDIT total score, ISI total score,
Altman total score, and the BSI global severity index, or GSI)
using ANCOVAwith the primary outcome measure as depen-
dent variable, group (SC vs NC) as independent variable, and
age and gender as covariates. The nine categories in the BSI
were then analyzed separately using this same method.
Clinical outcome analysis
To analyze the relative risk of clinically relevant mental health
problems of SC use compared to NC use we investigated the
categorical outcome measures of the questionnaires.
The DUDIT has three outcome categories related to the
total score: no problems (< 6), drug abuse (6–19), and drug
dependence (20+). We compared the no problem group to the
other two groups.
The ISI has four outcome categories related to the total
score: no significant insomnia (< 8), subthreshold insomnia
(8–14), clinical insomnia (15–21), and severe clinical insom-
nia (22+). We compared the participants with clinical and
severe clinical insomnia groups to the participants with no or
subthreshold insomnia.
The Altman mania scale has two outcome categories: no
manic symptoms (< 6) or (hypo)manic symptoms (6+). These
outcome categories were compared.
The BSI judges an individual to be a potential psychiatric
case with a GSI score equal to or greater than a T-score of 63.
For adult non-patients this translates to a GSI score of 0.58 for
men and 0.78 for women according to Appendix A of the BSI
manual (Derogatis 1993). Participants were assigned to two
groups (psychiatric problems or not) accordingly.
These categories were analyzed using logistic regression,
with user group (SC or NC) as independent variable, clinical
category as dependent variable, and age and gender as covar-
iates. Bias-corrected accelerated bootstrapping was used to
produce confidence intervals.
Results
Participants
The total number of responses was 589 SC users and 417 NC
users. From this total, cases were removed if they did not give
explicit consent, if they did not provide an age over 18 or
gender, if they did not complete at least one of the question-
naires, and if they did not explicitly state they had used NC
(for the NC users) or SC (for the SC users) in the past year.
After removing these cases, we included 367 participants from
three different countries: 238 SC users and 129 NC users (see
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Table 1). For all analyses, cases with missing data on any
measure were pairwise excluded.
Age and gender
There was no difference in age between the SC and NC user
groups (F(1,365) = 0.575, p = 0.449). There were fewer wom-
en in the SC user group (21%) than in the NC user group
(30%) (chi2 = 8.308, p = 0.016).
Substance use
There was a difference in frequency of use (chi2 = 100.029,
p < 0.001), with significantly fewer SC users (30%) reporting
monthly or more frequent SC use than the NC use among the
NC users group (84%). There was no difference in duration of
use (as calculated by the intervals for age of onset and current
age of SC use and NC use) between the NC user group and the
SC user group.
Use of 12 psychoactive drugs in the previous year and past
2 weeks was assessed. NC use was also highly prevalent in the
SC user group; SC use was non-prevalent in the NC user
group however. NC use was lower in the SC user group only
in the last 2 weeks of reported substance use. In addition,
salvia was used by more SC users in the past 2 weeks and past
12 months (8.5%) than NC users (0%). There was no differ-
ence between groups for all other substances at a Bonferroni
corrected p value of 0.004 (see Tables 2 and 3).
Psychometric instruments
The SC user group showed a higher DUDIT total score than
the NC user group (F(1,357) = 21.336, p = 0.000, eta2 =
0.056). Adjusted means: SC user group 13.73 (95% CI
12.49–14.96), NC user group 9.36 (95% CI 8.30–10.40).
Likewise, the SC user group showed a higher ISI total score
than the NC user group (F(1,222) = 20.052, p < 0.001, eta2 =
0.083). Adjusted means: SC 9.66 (95% CI 8.50–10.83), NC
5.60 (95% CI 4.61–6.70) (Table 4).
The Altman total score was higher in the SC user group than
the NC user group (F(1,229) = 23.982, p < 0.001, eta2 = 0.095).
Adjusted means: SC 3.84 (95% CI 3.23–4.43), NC 1.72 (95%
CI 1.27–2.14). The SC user group showed a higher GSI total
score compared to the NC user group (F(1,289) = 49.936, p =
0.000, eta2 = 0.147). Adjusted means: SC 1.00 (95% CI 0.87–
1.14), NC 0.38 (95% CI 0.31–0.44). This was the case for all
nine BSI categories underlying the GSI (Table 5).
Clinical outcome analysis
Using logistic regression to examine the clinical outcome mea-
sures of the psychometric instruments, we found that partici-
pants in the SC user group were between 3.56 and 5.21 times
more likely than participants in the NC user group to score in
the clinical range of the psychometric instruments (Table 6).
Discussion
In this study we found that compared to NC use, SC use is
more strongly associated with a broad range of self-reported
mental health problems. The SC user group scored significant-
ly higher on all measured indices of general and specific psy-
chopathology, and odds of scoring in the clinical range on any
of our measurements were 3.5 to over 5 times higher in the SC
user group compared to the NC user group. These results
warrant serious concern about SC use.
Few studies have attempted to investigate mental health
problems associated with SC use in a non-clinical population.
In a clinical population differences between NC and SC users
were observed, indicating an association of SC use with psy-
chotic problems, agitation, and longer hospitalizations (Bassir
Nia et al. 2016; Shalit et al. 2016). While the studied popula-
tions are very different, this supports our findings of more
severe problems related to SC use compared to NC use. On
our main index of psychiatric problems, the BSI, SC users
have higher scores than NC users on the GSI and all underly-
ing categories. The probability (odds ratio) of the GSI to ex-
ceed the threshold for a psychiatric diagnosis, as is formulated
in the BSI manual (Derogatis 1993), is five times higher for
participants in the SC group than the NC group. This is espe-
cially worrying considering that many studies have found that
NC use itself is already more often associated with psychiatric
problems, including depression, anxiety, and in particular psy-
chotic symptoms and schizophrenia (Moore et al. 2007;
Volkow et al. 2014).
Aside from the general psychiatric problems indexed by
the BSI, the results from the other psychometric measures
were also in line with previous studies. Cannabis use has been
associated with insomnia symptoms and impairment of sleep
Table 1 Participant information
Substance Age range
(years old)
Mean age
(years old ± SD)
Women Men Other
SC users (N = 238) 18–66 27.6 (± 8.5) 51 (21%) 177 (74%) 10 (4%)
NC users (N = 129) 18–71 27.7 (± 10.2) 39 (30%) 90 (70%) 0 (0%)
SD standard deviation, SC synthetic cannabis, NC natural cannabis
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quality in various studies (Babson et al. 2017; P. Gates et al.
2016; P. J. Gates et al. 2014). Mainly, long-term use of can-
nabis (mainly the chief component THC) seems to have a
negative impact on sleep quality, whereas some cannabinoids
show some promise for treatment of insomnia (Babson et al.
2017). However, the causative relationship of cannabis and
insomnia remains unclear and insomnia might as well be a
risk factor for adolescent cannabis use (Roane and Taylor
2008). Notwithstanding cause and effect, our study confirms
a relationship between insomnia symptoms and the use of
cannabinoid receptor agonists, whereby use of SCs is associ-
ated with poorer sleep quality than use of NC.
Cannabis use has also been associated with increased risk
of mania and subsequent bipolar disorder (Strakowski et al.
2007). Individuals with bipolar disorder were 6.8 times more
likely to report a lifetime history of cannabis use (Agrawal
et al. 2011). Cannabis use may also cause incidental episodes
ofmania or even long-term bipolar disorder, with cannabis use
often preceding onset of the first mania (Bally et al. 2014;
Henquet et al. 2006). Furthermore, NC use was also associat-
ed with a younger age of onset of the first mania and an
exacerbation of depressive and manic symptomatology in pa-
tients diagnosed with bipolar disorder (Bally et al. 2014;
Gibbs et al. 2015). The results of our study underline this
association between the cannabinoid system and mania, while
demonstrating that SCs show a greater association with mania
or bipolar disorder.
NC use may also lead to substance use disorders or depen-
dence (Hall and Degenhardt 2009). The results of our study
suggest a much higher dependence liability of SCs than NC.
Table 3 Additional psychoactive
drug use in the past 2 weeks Drug NC user group SC user group Chi
2
Natural cannabis 74.7% 21.3% 7.862, p = 0.002*
Amphetamines 11.0% 21.5% 3.594, p = 0.071
Cocaine/crack 6.1% 12.3% 2.419, p = 0.155
Tranquilizers 7.1% 17.1% 4.634, p = 0.044
Ecstasy/MDMA 3.4% 7.3% 1.735, p = 0.212
LSD/other hallucinogens 2.1% 6.9% 4.865, p = 0.033
Magic mushrooms 0.0% 3.8% 4.512, p = 0.046
GHB/GBL 0.0% 1.4% 3.855, p = 0.085
Ketamine 1.2% 7.3% 6.138, p = 0.120
Amyl nitrate/poppers 4.1% 1.4% 0.560, p = 0.517
Salvia divinorum 0.0% 8.4% 9.929, p = 0.000*
Nitrous oxide/laughing gas 3.4% 4.9% 0.982, p = 0.381
Methylone 3.6% 1.6% 6.950, p = 0.013
SC synthetic cannabis, NC natural cannabis
*Significant at Bonferroni-corrected p = 0.004
Table 2 Additional psychoactive
drug use in past 12 months Drug NC user group SC user group Chi
2
Natural cannabis 100.0% 81.5% 2.561, p = 0.126
Amphetamines 18.7% 31.3% 3.871, p = 0.051
Cocaine/crack 9.0% 15.4% 2.888, p = 0.115
Tranquilizers 9.3% 19.2% 4.925, p = 0.024
Ecstasy/MDMA 5.4% 9.3% 2.056, p = 0.189
LSD/other hallucinogens 4.8% 7.5% 3.974, p = 0.067
Magic mushrooms 0.7% 4.2% 4.041, p = 0.087
GHB/GBL 0.0% 1.9% 4.122, p = 0.065
Ketamine 2.0% 8.1% 6.877, p = 0.106
Amyl nitrate/poppers 4.1% 1.4% 0.711, p = 0.612
Salvia divinorum 0.0% 8.8% 9.129, p = 0.000*
Nitrous oxide/laughing gas 4.1% 5.6% 0.874, p = 0.471
Methylone 4.6% 3.8% 2.125, p = 0.231
SC synthetic cannabis, NC natural cannabis
*Significant at Bonferroni-corrected p = 0.004
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There is evidence to suggest that SCs, with a much greater
potency and affinity for the endocannabinoid system, are ca-
pable of inducing dependence. For instance, recent neuroim-
aging research showed a modest, but significant increase of
striatal dopamine in humans after cannabis use and also im-
paired striatal release in dependent cannabis users (Bossong
et al. 2009; van de Giessen et al. 2017). Our findings of a
higher DUDIT score for SC users are supported by a study
executed among high school students, showing higher sub-
stance use disorder psychopathology (Blevins et al. 2016).
The higher DUDIT score in the SC user group cannot be
attributed to frequency of use, which was higher for NC in
the NC user group. However, it has to be stipulated that the
DUDIT is not able to differentiate between which specific
substance is most likely to be underlying increased DUDIT
scores and most users are poly-drug users.
Our results on SCs are also supported by in vitro and ani-
mal studies at the moment. The pharmacological effects are
similar to themain active ingredient of NC:Δ9-THC, but with
a much greater binding affinity for the cannabinoid receptors,
in particular the cannabinoid 1 receptor (CB1R) (Castaneto
et al. 2014; Martinotti et al. 2017). This role as a potent
CB1R agonist has been observed to cause disturbed synaptic
functioning, potentially much stronger in SCs than Δ9-THC
which is a partial agonist (Hoffman et al. 2017). Furthermore,
SC mixtures or SCs alone do not contain cannabidiol, a com-
pound found in NC that is associated with reducing psychotic
experiences and anxiety, further increasing the potential risk
of mental health problems emerging after the use of SCs (Di
Forti et al. 2015; Murray et al. 2016; van Amsterdam et al.
2015). Even though there is much debate on the causality of
NC use and psychiatric problems, potent activation of CB1
receptors by increasingly potent agonists is a likely mecha-
nism to cause long-term brain changes (Haney and Evins
2016). Combining our findings of much higher scores on all
indices of psychiatric problems with the knowledge from
in vitro and animal studies about SC potency, again strong
caution is warranted in the case of SC use.
While our data clearly reveal that SC use is associated with
increased mental health problems, there are some limitations
to the study. First of all, it is a study which relies on effects and
symptoms that are self-reported on recall basis. And, because
it is a cross-sectional study, no statements can be made regard-
ing causality as we do not know if SC leads to increased
mental health problems, or if mental health problems instigate
SC use. To investigate causality, future studies should employ
a longitudinal design. In addition, the fact that the majority of
SC users also used NC in the past year might substantially
confound current findings, since effects of NC could be un-
derlying effects associated with the SC using group. Still, it
does not confound the magnitude in difference in symptoms
found between the two groups. There were no general statis-
tical differences found in most other substances used between
these two groups. However, we cannot discount the role other
drugs in the development of mental health status of our par-
ticipants. Furthermore, recruitment methods might underlie
some differences we found, as different drug-related forums
and social media were used to suit each country, which might
have resulted in bias. However, they were selected to optimize
sample size, and using identical recruitment platforms, if even
possible, would have likely led to small sample sizes with its
own limitations. Since this study is based on data acquired
using an online survey, the veracity of the answers cannot be
determined. Notwithstanding this argument, online surveys do
not appear to differ from traditional surveys in this regard
(Miller et al. 2002). Finally, we have no information on the
subtype or amount of SC used by the participants.
Unfortunately, this mimics the real-world situation and
Table 4 Means adjusted for
gender and age, between-subject
significance, and partial eta
squared for the effect of group on
the questionnaires
Questionnaire NC adjusted mean SC adjusted mean p Partial eta2
DUDIT 9.36 13.73 < 0.001 0.056
ISI 5.60 9.66 < 0.001 0.083
Altman 1.72 3.84 < 0.001 0.095
BSI (GSI) 0.38 1.00 < 0.001 0.147
DUDIT Drug Use Disorders Identification Test, ISI Insomnia Severity Index, BSI Brief Symptom Inventory, GSI
General Symptom Inventory, SC synthetic cannabis, NC natural cannabis
Table 5 The 95% confidence intervals adjusted for gender and age,
between-subject significance, and partial eta squared for the effect of
group on BSI category score
BSI category NC 95% CI SC 95% CI p Partial eta2
Somatization 0.23–0.36 0.61–0.87 < 0.001 0.088
Obsessive-compulsive 0.49–0.72 1.20–1.53 < 0.001 0.131
Interpersonal
sensitivity
0.30–0.49 0.77–1.10 < 0.001 0.078
Depression 0.43–0.70 1.05–1.39 < 0.001 0.088
Anxiety 0.24–0.42 1.00–1.32 < 0.001 0.173
Hostility 0.15–0.28 0.58–0.86 < 0.001 0.089
Phobic anxiety 0.19–0.36 0.77–1.10 < 0.001 0.115
Paranoid ideation 0.17–0.28 0.75–1.05 < 0.001 0.149
Psychoticism 0.27–0.45 0.67–0.98 < 0.001 0.068
BSI Brief Symptom Inventory, CI confidence interval, SC synthetic can-
nabis, NC natural cannabis
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highlights an additional danger of SC use. There is significant
variance of subtype and quantity of SCs, even between pack-
ages with the same name (Fattore 2016).
Our study demonstrates that there are significant mental
health problems in this population of SC users, which should
be cause for concern for treatment and prevention profes-
sionals. Use of SCs is associated with a probability for mental
health risks up to over five times greater than NC use, which is
in line with previous results assembled in clinical and preclin-
ical (experimental animal) studies with SCs which showed a
much more potent mechanism of action than NC. This study
should be considered as a strong caution about the potential
danger of SC use to mental health.
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